Clinically Isolated Syndrome: Clinical Trials

4 trials for Clinically Isolated Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Completed 3, Active not recruiting 1

Follow Clinically Isolated Syndrome: new trials by email Literature Review of Clinically Isolated Syndrome trials Research Report on Clinically Isolated Syndrome

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
Ocrelizumab - Multiple Sclerosis, Clinically Isolated Syndrome
Phase 4CompletedHoffmann-La Roche702022-04-132026-04-15
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
Ocrelizumab - Multiple Sclerosis, Clinically Isolated Syndrome
Phase 4CompletedHoffmann-La Roche262021-09-162026-01-14
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Ocrelizumab - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Phase 4Active not recruitingUniversity of California, San Francisco302020-08-302026-01-26
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™
Rebif - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Phase 4CompletedMerck KGaA, Darmstadt, Germany1062014-12-312018-03-30

Narrower conditions

Multiple Sclerosis (2)  ·  Breast Feeding (1)

Broader conditions

Autoimmune Diseases (2)  ·  Autoimmune Diseases of the Nervous System (2)  ·  Demyelinating Autoimmune Diseases, CNS (2)  ·  Demyelinating Diseases (2)  ·  Immune System Diseases (2)  ·  Nervous System Diseases (2)  ·  Behavior (1)  ·  Feeding Behavior (1)

Interventions

ocrelizumab (3)  ·  Interferon beta-1a (1)

Sponsors

Hoffmann-La Roche (2)  ·  Merck KGaA, Darmstadt, Germany (1)  ·  University of California, San Francisco (1)

Countries

United States (3)  ·  Germany (2)  ·  Spain (2)  ·  France (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Bruce Cree, MD, PhD, MAS (1)

NIH funding

2014 (1)